Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: Two double-blind randomized clinical trials

John Grabowski, Howard Rhoades, Angela Stotts, Katherine Cowan, Charles Kopecky, Anne Dougherty, F. Gerard Moeller, Sohela Hassan, Joy Schmitz

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Concurrent abuse of cocaine and heroin is a common problem. Methadone is effective for opioid dependence. The question arises as to whether combining agonist-like or antagonist-like medication for cocaine with methadone for opioid dependence might be efficacious. Two parallel studies were conducted. One examined sustained release d-amphetamine and the other risperidone for cocaine dependence, each in combination with methadone. In total, 240 subjects (120/study) were recruited, who were both cocaine and heroin dependent and not currently receiving medication. All provided consent. Both studies were carried out for 26 weeks, randomized, double-blind and placebo controlled. Study I compared sustained release d-amphetamine (escalating 15-30 or 30-60 mg) and placebo. Study II examined risperidone (2 or 4 mg) and placebo. All subjects underwent methadone induction and were stabilized at 1.1 mg/kg. Subjects attended clinic twice/week, provided urine samples, obtained medication take-home doses for intervening days, and completed self-report measures. Each had one behavioral therapy session/week. In Study I, reduction in cocaine use was significant for the 30/60 mg dose compared to the 15/30 mg and placebo. Opioid use was reduced in all groups with a trend toward greater reduction in the 30/ 60 mg d-amphetamine group. In Study II, methadone reduced illicit opioid use but cocaine use did not change in the risperidone or placebo groups. There were no adverse medication interactions in either study. The results provide support for the agonist-like (d-amphetamine) model in cocaine dependence treatment but not for antagonist-like (risperidone) treatment. They coincide with our previous reports of amphetamine or risperidone administered singly in cocaine-dependent individuals.

Original languageEnglish (US)
Pages (from-to)969-981
Number of pages13
JournalNeuropsychopharmacology
Volume29
Issue number5
DOIs
StatePublished - May 1 2004

Fingerprint

Heroin Dependence
Cocaine-Related Disorders
Risperidone
Methadone
Dextroamphetamine
Cocaine
Randomized Controlled Trials
Opioid Analgesics
Placebos
Therapeutics
Heroin
Amphetamine
Self Report
Urine

Keywords

  • Cocaine abuse
  • Cocaine/heroin pharmacotherapy
  • Dual dependence
  • Heroin abuse
  • Risperidone
  • Treatment
  • d-amphetamine

Cite this

Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence : Two double-blind randomized clinical trials. / Grabowski, John; Rhoades, Howard; Stotts, Angela; Cowan, Katherine; Kopecky, Charles; Dougherty, Anne; Moeller, F. Gerard; Hassan, Sohela; Schmitz, Joy.

In: Neuropsychopharmacology, Vol. 29, No. 5, 01.05.2004, p. 969-981.

Research output: Contribution to journalArticle

Grabowski, John ; Rhoades, Howard ; Stotts, Angela ; Cowan, Katherine ; Kopecky, Charles ; Dougherty, Anne ; Moeller, F. Gerard ; Hassan, Sohela ; Schmitz, Joy. / Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence : Two double-blind randomized clinical trials. In: Neuropsychopharmacology. 2004 ; Vol. 29, No. 5. pp. 969-981.
@article{8c60059a41cf462db1980f1a5e88e7fa,
title = "Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: Two double-blind randomized clinical trials",
abstract = "Concurrent abuse of cocaine and heroin is a common problem. Methadone is effective for opioid dependence. The question arises as to whether combining agonist-like or antagonist-like medication for cocaine with methadone for opioid dependence might be efficacious. Two parallel studies were conducted. One examined sustained release d-amphetamine and the other risperidone for cocaine dependence, each in combination with methadone. In total, 240 subjects (120/study) were recruited, who were both cocaine and heroin dependent and not currently receiving medication. All provided consent. Both studies were carried out for 26 weeks, randomized, double-blind and placebo controlled. Study I compared sustained release d-amphetamine (escalating 15-30 or 30-60 mg) and placebo. Study II examined risperidone (2 or 4 mg) and placebo. All subjects underwent methadone induction and were stabilized at 1.1 mg/kg. Subjects attended clinic twice/week, provided urine samples, obtained medication take-home doses for intervening days, and completed self-report measures. Each had one behavioral therapy session/week. In Study I, reduction in cocaine use was significant for the 30/60 mg dose compared to the 15/30 mg and placebo. Opioid use was reduced in all groups with a trend toward greater reduction in the 30/ 60 mg d-amphetamine group. In Study II, methadone reduced illicit opioid use but cocaine use did not change in the risperidone or placebo groups. There were no adverse medication interactions in either study. The results provide support for the agonist-like (d-amphetamine) model in cocaine dependence treatment but not for antagonist-like (risperidone) treatment. They coincide with our previous reports of amphetamine or risperidone administered singly in cocaine-dependent individuals.",
keywords = "Cocaine abuse, Cocaine/heroin pharmacotherapy, Dual dependence, Heroin abuse, Risperidone, Treatment, d-amphetamine",
author = "John Grabowski and Howard Rhoades and Angela Stotts and Katherine Cowan and Charles Kopecky and Anne Dougherty and Moeller, {F. Gerard} and Sohela Hassan and Joy Schmitz",
year = "2004",
month = "5",
day = "1",
doi = "10.1038/sj.npp.1300392",
language = "English (US)",
volume = "29",
pages = "969--981",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence

T2 - Two double-blind randomized clinical trials

AU - Grabowski, John

AU - Rhoades, Howard

AU - Stotts, Angela

AU - Cowan, Katherine

AU - Kopecky, Charles

AU - Dougherty, Anne

AU - Moeller, F. Gerard

AU - Hassan, Sohela

AU - Schmitz, Joy

PY - 2004/5/1

Y1 - 2004/5/1

N2 - Concurrent abuse of cocaine and heroin is a common problem. Methadone is effective for opioid dependence. The question arises as to whether combining agonist-like or antagonist-like medication for cocaine with methadone for opioid dependence might be efficacious. Two parallel studies were conducted. One examined sustained release d-amphetamine and the other risperidone for cocaine dependence, each in combination with methadone. In total, 240 subjects (120/study) were recruited, who were both cocaine and heroin dependent and not currently receiving medication. All provided consent. Both studies were carried out for 26 weeks, randomized, double-blind and placebo controlled. Study I compared sustained release d-amphetamine (escalating 15-30 or 30-60 mg) and placebo. Study II examined risperidone (2 or 4 mg) and placebo. All subjects underwent methadone induction and were stabilized at 1.1 mg/kg. Subjects attended clinic twice/week, provided urine samples, obtained medication take-home doses for intervening days, and completed self-report measures. Each had one behavioral therapy session/week. In Study I, reduction in cocaine use was significant for the 30/60 mg dose compared to the 15/30 mg and placebo. Opioid use was reduced in all groups with a trend toward greater reduction in the 30/ 60 mg d-amphetamine group. In Study II, methadone reduced illicit opioid use but cocaine use did not change in the risperidone or placebo groups. There were no adverse medication interactions in either study. The results provide support for the agonist-like (d-amphetamine) model in cocaine dependence treatment but not for antagonist-like (risperidone) treatment. They coincide with our previous reports of amphetamine or risperidone administered singly in cocaine-dependent individuals.

AB - Concurrent abuse of cocaine and heroin is a common problem. Methadone is effective for opioid dependence. The question arises as to whether combining agonist-like or antagonist-like medication for cocaine with methadone for opioid dependence might be efficacious. Two parallel studies were conducted. One examined sustained release d-amphetamine and the other risperidone for cocaine dependence, each in combination with methadone. In total, 240 subjects (120/study) were recruited, who were both cocaine and heroin dependent and not currently receiving medication. All provided consent. Both studies were carried out for 26 weeks, randomized, double-blind and placebo controlled. Study I compared sustained release d-amphetamine (escalating 15-30 or 30-60 mg) and placebo. Study II examined risperidone (2 or 4 mg) and placebo. All subjects underwent methadone induction and were stabilized at 1.1 mg/kg. Subjects attended clinic twice/week, provided urine samples, obtained medication take-home doses for intervening days, and completed self-report measures. Each had one behavioral therapy session/week. In Study I, reduction in cocaine use was significant for the 30/60 mg dose compared to the 15/30 mg and placebo. Opioid use was reduced in all groups with a trend toward greater reduction in the 30/ 60 mg d-amphetamine group. In Study II, methadone reduced illicit opioid use but cocaine use did not change in the risperidone or placebo groups. There were no adverse medication interactions in either study. The results provide support for the agonist-like (d-amphetamine) model in cocaine dependence treatment but not for antagonist-like (risperidone) treatment. They coincide with our previous reports of amphetamine or risperidone administered singly in cocaine-dependent individuals.

KW - Cocaine abuse

KW - Cocaine/heroin pharmacotherapy

KW - Dual dependence

KW - Heroin abuse

KW - Risperidone

KW - Treatment

KW - d-amphetamine

UR - http://www.scopus.com/inward/record.url?scp=1942484846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942484846&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1300392

DO - 10.1038/sj.npp.1300392

M3 - Article

C2 - 15039761

AN - SCOPUS:1942484846

VL - 29

SP - 969

EP - 981

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 5

ER -